Endoluten®
Dynamics of subjective indicators in patients with climacteric Table 3
syndrome.
Indicator Number of patients, (%)
Before Treatment After Treatment with After Treatment with
Conventional Means (Control Endoluten® (Primary Group)
Group)
Hot flushes in the head and upper body 78,0 59,4* 26,2*#
Increased sweating 72,6 54,1* 23,2*#
Headaches 63,4 48,3 35,2*
Changes in blood pressure 53,1 37,3 26,2*#
Pain in theheart region 59,4 38,8* 23,5*#
Tachycardia attacks 68,4 45,1* 22,4*#
Dizziness 43,8 31,2* 26,3*
Weakness 61,5 46,4 30,0*
Feeling of "sinking" heart 52,8 27,2* 24,6*
Fast fatiguability 85,2 53,9* 32,6*#
Reduced performance 86,8 56,2* 38,4*#
Irritability 93,1 62,5* 36,1*#
Tearfulness 54,2 34,8* 22,3*#
Sleep disturbance 76,8 47,6* 22,1*#
Decreased memory and attention 57,1 43,2 32,7*
* p <0.05 compared with the indicator in patients before treatment;
#p <0.05 compared with the indicator in patients after treatment with conventional means.
ENDOLUTEN® was also used in the complex therapy of men with physiogenic asthenia. The
drug had a pronounced corrective effect on the dynamics of subjective indicators. Men suffering
from physiogenic asthenia complained of general weakness, dizziness, increased fatigue, reduced
efficiency, and sleep disturbance. The additional inclusion of ENDOLUTEN® in the treatment
regimen of this category of patients led to the relief of subjective symptoms, which contributed
to a rapid and effective improvement in the general condition, while in the control group patients
who received only conventional therapy, the improvement in their condition occurred exceptionally
slowly, and after the cessation of the course of treatment subjective neurological symptoms
returned. It is important to note that when ENDOLUTEN® was used, a pronounced aftereffect was
observed: after discontinuation of the drug, the improvement in the patients’ condition continued
and persisted during the observation period - at least 1-3 months.
Thus, the use of ENDOLUTEN® is a promising direction in the treatment of pathological conditions
associated with impaired neurovegetative regulation, including climacteric syndrome, physiogenic
asthenia, vegetative-vascular dystonia, and other psychovegetative disorders.
ENDOLUTEN® was also used in cancer patients, mainly in hormone-dependent tumors (breast
cancer, cervical cancer, other localizations), after surgical treatment, and courses of radiation
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.